New York, NY / ACCESSWIRE / September 29, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has initiated coverage on Innovus Pharmaceuticals, Inc. (INNV), an emerging pharmaceutical company engaged in the commercialization, licensing, and development of non-prescription medicines and consumer care products to improve men’s and women’s health and vitality.

Innovus is entering an exciting phase of growth as it is pursuing accentuated marketing efforts in the US through 25 partner sales reps to physicians and also signed three significant international distribution agreements in September with substantial partners to commercialize its products in 28 countries,” stated Ajay Tandon, CEO of SeeThruEquity. “We are watching for new developments closely and are initiating coverage with a target price of $1.34.”

Additional investment highlights are as follows:

Unique business model

Innovus employs a unique business model that focuses on acquiring clinically-proven products with established sales channels in the niche male and female sexual dysfunction OTC and consumer care market. Additionally, the company leverages established commercial partners in underserved geographies for selling its products and the extensive commercial partners they established in 28 countries. The strategy not only results in minimal investments in R&D but also provides the company with strong sales channels internationally. INNV acquired its revenue-generating products Zestra(r) to enhance arousal and desire in women and Zestra Glide(r) a high viscosity water based lubricant from Semprae Laboratories, Inc. in late 2013. It launched its topical treatment for premature ejaculation, EjectDelay(tm), in 2014 and licensed Ex-U.S. rights to SenSum+(tm) to increase penile sensitivity from Centric Research Institute (CRI) in 2Q13.

Aggressive marketing strategy to drive Zestra(r) sales in the U.S.

In August 2014, Innovus commenced direct promotion of its lead product, Zestra(r) to enhance arousal and desire in women to gynecologists and therapists through the 25 sales force representatives of its partner, Consortia Health, and has concurrently initiated a Nationwide Marketing and Sales Campaign to U.S. Gynecologists for Zestra(r). We believe the aggressive marketing campaign will ensure that U.S. gynecologists and therapists know about Zestra(r) and have clinical use experience with their patients, resulting in significant ramp up in the sales of Zestra(r) starting 2015. Recently (Sept 8, 2014), Innovus also expanded US distribution for Zestra(r) by signing a non-exclusive sampling and distribution agreement with Bulu Box, a premium vitamin and supplement sample subscription company. As part of the agreement, Bulu Box will add Zestra as part of its monthly box to all current subscribers and will sell Zestra(r) 3 packettes box through its E-commerce platform in the U.S.

Expanding global presence

INNV currently markets its products in the U.S. and Canada. To expand its reach to regions outside North America and expand its marketing footprint in Canada, the company is pursuing an aggressive commercial partnering and distribution strategy. In August 2014, Innovus inked an exclusive marketing and distribution agreement with Denmark-based DanaLife, granting DanaLife an exclusive 18 month global distribution rights (excluding Canada), to market and sell Zestra(r) for alternative markets which excludes all medical and mainstream sales channels. This agreement provides an opportunity to expand into the large additional sales channels for female products worth an estimated $2 billion. In September 2013, INNV inked two distribution agreements (one each for Sensum+(tm) and EjectDelay(tm)) with Ovation Pharma to market and sell the products in Morocco. Under the agreement, INNV may receive up to $30mn in upfront and commercial milestones. Recently (September 2014), INNV signed three international distribution agreements – with Tramorgan Limited for Sensum+(tm) in the UK; with Orimed for Zestra(r), EjectDelay(tm), Sensum+(tm) and Zestra Glide(r) in Canada; and with Sothema Laboratories for Zestra(r) and Zestra Glide(r) in the Middle East, North and West Africa. The three agreements may result in combined upfront/sales milestone payments of over ~$270mn and potentially allow the Company to have its products sold in 28 countries.

The report is available here: INNV Initiation Report. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack’s. The report will also be available on these platforms.

Please review important disclosures on our website at http://www.seethruequity.com/.

About Innovus Pharmaceuticals, Inc.

Innovus Pharmaceuticals, Inc. (INNV), located in San Diego, California, is an emerging pharmaceuticals company that delivers safe, innovative and effective non-prescription over-the counter medicine and consumer care products to improve men and women's health and vitality. Our products are marketed in the United States, Canada and elsewhere via retailers and on the web. The Company also details its products to urologists, gynecologists and sex therapists either directly in the United States or through commercial partners, ex-U.S.

For more information, go to http://www.innovuspharma.com/.

About SeeThruEquity

SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for and is unbiased. We do not conduct any investment banking or commission based business. We are approved to contribute our research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks and distribute our research to our database of opt-in investors. We also contribute our estimates to Thomson Estimates, the leading estimates platform on Wall Street.

For more information visit http://www.seethruequity.com/.

Contact:

Ajay Tandon
SeeThruEquity
(646) 495-0939

Source: SeeThruEquity